Anzeige
Mehr »
Login
Dienstag, 23.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News: InnoCan startet in eine neue Ära – FDA Zulassung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
1.010 Leser
Artikel bewerten:
(2)

Veeco Instruments Inc.: Veeco Reports Third Quarter 2022 Financial Results

Third Quarter 2022 Highlights:

  • Revenues of $171.9 million, compared with $150.2 million in the same period last year
  • GAAP net income of $15.0 million, or $0.27 per diluted share, compared with $9.0 million, or $0.17 per diluted share in the same period last year
  • Non-GAAP net income of $26.0 million, or $0.45 per diluted share, compared with $20.5 million, or $0.40 per diluted share in the same period last year

PLAINVIEW, N.Y., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Veeco Instruments Inc. (Nasdaq: VECO) today announced financial results for its third quarter ended September 30, 2022. Results are reported in accordance with U.S. generally accepted accounting principles ("GAAP") and are also reported adjusting for certain items ("Non-GAAP"). A reconciliation between GAAP and Non-GAAP operating results is provided at the end of this press release.

U.S. Dollars in millions, except per share data
       
GAAP Results Q3 '22 Q3 '21
Revenue $171.9 $150.2
Net income $15.0 $9.0
Diluted earnings per share $0.27 $0.17


       
Non-GAAP Results Q3 '22 Q3 '21
Operating income $28.4 $24.3
Net income $26.0 $20.5
Diluted earnings per share $0.45 $0.40

"With significant contributions from our laser annealing product line, as well as systems for advanced packaging and EUV mask blank production, we achieved another record revenue quarter in our semiconductor business which drove robust year-on-year revenue growth for the company," commented Bill Miller, Veeco's Chief Executive Officer. "Despite the challenging current macro environment, we continue to invest in executing our growth strategy, are well positioned with attractive technologies and we are optimistic about expanding our served available market."

Guidance and Outlook

The following guidance is provided for Veeco's fourth quarter 2022:

  • Revenue is expected in the range of $150 million to $170 million
  • GAAP diluted earnings per share are expected in the range of $0.05 to $0.23
  • Non-GAAP diluted earnings per share are expected in the range of $0.24 to $0.40

Conference Call Information

A conference call reviewing these results has been scheduled for today, November 7, 2022 starting at 5:00pm ET. To join the call, dial 1-866-580-3963 (toll free) or 1-786-697-3501 and use password VECOQ32022. Participants may also access a live webcast of the call by visiting the investor relations section of Veeco's website at ir.veeco.com. A replay of the webcast will be made available on the Veeco website that evening. We will post an accompanying slide presentation to our website prior to the beginning of the call.

About Veeco

Veeco (NASDAQ: VECO) is an innovative manufacturer of semiconductor process equipment. Our proven ion beam, laser annealing, lithography, MOCVD, and single wafer etch & clean technologies play an integral role in the fabrication and packaging of advanced semiconductor devices. With equipment designed to optimize performance, yield and cost of ownership, Veeco holds leading technology positions in the markets we serve. To learn more about Veeco's systems and service offerings, visit www.veeco.com.

Forward-looking Statements

This press release contains "forward-looking statements", within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, as amended, that are based on management's expectations, estimates, projections and assumptions. Words such as "expects," "anticipates," "plans," "believes," "scheduled," "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements. Forward-looking statements include, but are not limited to, those regarding anticipated growth and trends in our businesses and markets, industry outlooks and demand drivers, our investment and growth strategies, our development of new products and technologies, our business outlook for current and future periods, the impact of the COVID-19 pandemic, our ongoing transformation initiative and the effects thereof on our operations and financial results; and other statements that are not historical facts. These statements and their underlying assumptions are subject to risks and uncertainties and are not guarantees of future performance. Factors that could cause actual results to differ materially from those expressed or implied by such statements include, without limitation: the level of demand for our products; global economic and industry conditions; the effects of regional or global health epidemics, including the effects of the COVID-19 pandemic on the Company's operations and on those of our customers and suppliers; global trade issues, including the ongoing trade disputes between the U.S. and China, and changes in trade and export license policies; our dependency on third-party suppliers and outsourcing partners; the timing of customer orders; our ability to develop, deliver and support new products and technologies; our ability to expand our current markets, increase market share and develop new markets; the concentrated nature of our customer base; our ability to obtain and protect intellectual property rights in key technologies; our ability to achieve the objectives of operational and strategic initiatives and attract, motivate and retain key employees; the variability of results among products and end-markets, and our ability to accurately forecast future results, market conditions, and customer requirements; the impact of our indebtedness, including our convertible senior notes and our capped call transactions; and other risks and uncertainties described in our SEC filings on Forms 10-K, 10-Q and 8-K, and from time-to-time in our other SEC reports. All forward-looking statements speak only to management's expectations, estimates, projections and assumptions as of the date of this press release or, in the case of any document referenced herein or incorporated by reference, the date of that document. The Company does not undertake any obligation to update or publicly revise any forward-looking statements to reflect events, circumstances or changes in expectations after the date of this press release.

-financial tables attached-

Veeco Contacts:   
    
Investors:Anthony Bencivenga(516) 252-1438abencivenga@veeco.com
Media:Kevin Long(516) 714-3978klong@veeco.com 



Veeco Instruments Inc. and Subsidiaries

Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
(unaudited)

              
  Three months ended September 30, Nine months ended September 30, 
  2022  2021  2022  2021  
Net sales $171,913  $150,246  $492,338  $430,305  
Cost of sales  101,962   87,077   292,109   252,055  
Gross profit  69,951   63,169   200,229   178,250  
Operating expenses, net:             
Research and development  27,104   21,999   77,237   66,397  
Selling, general, and administrative  22,144   21,603   67,987   63,325  
Amortization of intangible assets  2,505   2,976   7,514   9,305  
Other operating expense (income), net  634   175   587   138  
Total operating expenses, net  52,387   46,753   153,325   139,165  
Operating income  17,564   16,416   46,904   39,085  
Interest expense, net  (2,315)  (7,012)  (7,753)  (20,221) 
Income before income taxes  15,249   9,404   39,151   18,864  
Income tax expense (benefit)  208   411   1,125   1,029  
Net income $15,041  $8,993  $38,026  $17,835  
              
Income per common share:             
Basic $0.30  $0.18  $0.76  $0.36  
Diluted $0.27  $0.17  $0.70  $0.33  
              
Weighted average number of shares:             
Basic  49,887   49,021   49,831   48,968  
Diluted  65,151   53,849   65,090   53,606  



Veeco Instruments Inc. and Subsidiaries

Condensed Consolidated Balance Sheets
(in thousands)

       
  September 30, December 31,
  2022 2021
  (unaudited)   
Assets      
Current assets:      
Cash and cash equivalents $169,111 $119,747
Restricted cash  557  725
Short-term investments  101,862  104,181
Accounts receivable, net  142,985  109,609
Contract assets  29,865  18,293
Inventories  187,737  170,858
Prepaid expenses and other current assets  17,586  25,974
Total current assets  649,703  549,387
Property, plant and equipment, net  108,416  99,743
Operating lease right-of-use assets  25,119  28,813
Intangible assets, net  26,391  33,905
Goodwill  181,943  181,943
Deferred income taxes  1,639  1,639
Other assets  3,406  3,546
Total assets $996,617 $898,976
       
Liabilities and stockholders' equity      
Current liabilities:      
Accounts payable $51,129 $44,456
Accrued expenses and other current liabilities  65,062  79,752
Customer deposits and deferred revenue  122,285  63,136
Income taxes payable  1,565  1,860
Current portion of long-term debt  20,144  
Total current liabilities  260,185  189,204
Deferred income taxes  4,748  4,792
Long-term debt  254,272  229,438
Long-term operating lease liabilities  31,266  32,834
Other liabilities  5,031  5,080
Total liabilities  555,502  461,348
       
Total stockholders' equity  441,115  437,628
Total liabilities and stockholders' equity $996,617 $898,976

Note on Reconciliation Tables

The below tables include financial measures adjusted for the impact of certain items; these financial measures are therefore not calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). These Non-GAAP financial measures exclude items such as: share-based compensation expense; charges relating to restructuring initiatives; non-cash asset impairments; certain other non-operating gains and losses; and acquisition-related items such as transaction costs, non-cash amortization of acquired intangible assets, and certain integration costs.

These Non-GAAP financial measures may be different from Non-GAAP financial measures used by other companies. Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. By excluding these items, Non-GAAP financial measures are intended to facilitate meaningful comparisons to historical operating results, competitors' operating results, and estimates made by securities analysts. Management is evaluated on key performance metrics including Non-GAAP Operating income (loss), which is used to determine management incentive compensation as well as to forecast future periods. These Non-GAAP financial measures may be useful to investors in allowing for greater transparency of supplemental information used by management in its financial and operational decision-making. In addition, similar Non-GAAP financial measures have historically been reported to investors; the inclusion of comparable numbers provides consistency in financial reporting. Investors are encouraged to review the reconciliation of the Non-GAAP financial measures used in this news release to their most directly comparable GAAP financial measures.

Reconciliation of GAAP to Non-GAAP Financial Data (Q3 2022)
(in thousands)
(unaudited)

              
     Non-GAAP Adjustments    
     Share-Based        
Three months ended September 30, 2022 GAAP Compensation Amortization Other Non-GAAP 
Net sales $171,913       $171,913 
Gross profit  69,951 1,195    1,102   72,248 
Gross margin  40.7%       42.0%
Operating expenses  52,387 (5,015) (2,505) (981)  43,886 
Operating income  17,564 6,210  2,505  2,083 ^ 28,362 
Net income  15,041 6,210  2,505  2,252 ^ 26,008 

 

______________________
^   - See table below for additional details.


Other Non-GAAP Adjustments (Q3 2022)

(in thousands)
(unaudited)

   
Three months ended September 30, 2022  
Transition expenses related to San Jose expansion project$1,936 
Depreciation of PP&E fair value step-up associated with the Ultratech purchase accounting 147 
Subtotal 2,083 
Non-cash interest expense 242 
Non-GAAP tax adjustment * (73)
Total Other$2,252 

 

______________________

*   - The 'with or without' method is utilized to determine the income tax effect of all Non-GAAP adjustments.


Net Income per Common Share (Q3 2022)

(in thousands, except per share amounts)
(unaudited)

       
  Three months ended September 30, 2022
  GAAP Non-GAAP
Numerator:      
Net income $15,041 $26,008
Interest expense associated with convertible notes  2,549  2,467
Net income available to common shareholders $17,590 $28,475
       
Denominator:      
Basic weighted average shares outstanding  49,887  49,887
Effect of potentially dilutive share-based awards  801  801
Dilutive effect of 2023 Convertible Senior Notes    504
Dilutive effect of 2025 Convertible Senior Notes  5,521  5,521
Dilutive effect of 2027 Convertible Senior Notes(1)  8,942  6,771
Diluted weighted average shares outstanding  65,151  63,484
       
Net income per common share:      
Basic $0.30 $0.52
Diluted $0.27 $0.45

 

______________________
(1) - The non-GAAP incremental dilutive shares includes the impact of the Company's capped call transaction issued concurrently with our 2027 Notes, and as such, an effective conversion price of $18.46 is used when determining incremental shares to add to the dilutive share count. The GAAP incremental dilutive shares does not include the impact of the Company's capped call transaction, and as such, an effective conversion price of $13.98 is used when determining incremental shares to add to the dilutive share count.


Reconciliation of GAAP to Non-GAAP Financial Data (Q3 2021)

(in thousands, except per share amounts)
(unaudited)

              
     Non-GAAP Adjustments    
     Share-based       
Three months ended September 30, 2021  GAAP Compensation Amortization Other Non-GAAP 
Net sales $150,246       $150,246 
Gross profit  63,169 620    150   63,939 
Gross margin  42.0%       42.6%
Operating expenses  46,753 (3,510) (2,976) (637)  39,630 
Operating income  16,416 4,130  2,976  787 ^ 24,309 
Net income  8,993 4,130  2,976  4,375 ^ 20,474 
              
Income per common share:             
Basic $0.18       $0.42 
Diluted  0.17        0.40 
Weighted average number of shares:             
Basic  49,021        49,021 
Diluted(1)  53,849        51,679 

 

______________________
^ - See table below for additional details.

(1) - The non-GAAP incremental dilutive shares includes the impact of the Company's capped call transaction issued concurrently with our 2027 Notes, and as such, no incremental shares are added to the dilutive share count in periods in which the average stock price per share is below $18.46. The GAAP incremental dilutive shares does not include the impact of the Company's capped call transaction, and as such, incremental shares are added to the dilutive share count in periods in which the average stock price per share is above $13.98, and the Company is in a net income position. The average stock price for the three months ended September 30, 2021 was $22.24, and therefore 1.2 million shares were included in the non-GAAP diluted share count, and 3.3 million shares were included in the GAAP diluted share count related to the 2027 Notes.


Other Non-GAAP Adjustments (Q3 2021)

(in thousands)
(unaudited)

   
Three months ended September 30, 2021  
Transition expenses related to San Jose expansion project$705 
Depreciation of PP&E fair value step-up associated with the Ultratech purchase accounting 82 
Subtotal 787 
Non-cash interest expense 3,663 
Non-GAAP tax adjustment * (75)
Total Other$4,375 

 

______________________
*   - The 'with or without' method is utilized to determine the income tax effect of all Non-GAAP adjustments.


Reconciliation of GAAP Net Income to Non-GAAP Operating Income (Q3 2022 and 2021)

(in thousands)
(unaudited)

       
  Three months ended Three months ended
  September 30, 2022 September 30, 2021
GAAP Net income $15,041 $8,993
Share-based compensation  6,210  4,130
Amortization  2,505  2,976
Transition expenses related to San Jose expansion project  1,936  705
Depreciation of PP&E fair value step-up associated with the Ultratech purchase accounting  147  82
Interest (income) expense, net  2,315  7,012
Income tax expense (benefit)  208  411
Non-GAAP Operating income $28,362 $24,309


Reconciliation of GAAP to Non-GAAP Financial Data (Q4 2022)

(in millions, except per share amounts)
(unaudited)

                        
          Non-GAAP Adjustments         
Guidance for the three months ending         Share-based             
December 31, 2022 GAAP Compensation Amortization Other Non-GAAP 
Net sales $150  - $170        $150  - $170  
Gross profit  56  -  68  1    1   58  -  70  
Gross margin  37% -  40%        39% -  41% 
Operating expenses  51  -  53  (5) (3) (1)  43  -  45  
Operating income  5  -  15  6  3  1   15  -  25  
Net income $2  - $12  6  3  2  $13  - $23  
                        
Income per diluted common share $0.05  - $0.23        $0.24  - $0.40  


Income per Diluted Common Share (Q4 2022)

(in millions, except per share amounts)
(unaudited)

                 
Guidance for the three months ending December 31, 2022 GAAP Non-GAAP
Numerator:                
Net income $2 - $12 $13 - $23
Interest expense associated with convertible notes      3  2    2
Net income available to common shareholders $2 - $15 $15 - $25
                 
Denominator:                
Basic weighted average shares outstanding  50    50  50    50
Effect of potentially dilutive share-based awards  1    1  1    1
Dilutive effect of 2023 Convertible Senior Notes            
Dilutive effect of 2025 Convertible Senior Notes      6  6    6
Dilutive effect of 2027 Convertible Senior Notes(1)      9  7    7
Diluted weighted average shares outstanding  51    66  64    64
                 
Net income per common share:                
Income per diluted common share $0.05 - $0.23 $0.24 - $0.40

______________________
(1) - The non-GAAP incremental dilutive shares includes the impact of the Company's capped call transaction issued concurrently with our 2027 Notes, and as such, an effective conversion price of $18.46 is used when determining incremental shares to add to the dilutive share count. The GAAP incremental dilutive shares does not include the impact of the Company's capped call transaction, and as such, an effective conversion price of $13.98 is used when determining incremental shares to add to the dilutive share count.


Reconciliation of GAAP Net Income to Non-GAAP Operating Income (Q4 2022)

(in millions)
(unaudited)

         
Guidance for the three months ending December 31, 2022        
GAAP Net income $2 - $12
Share-based compensation  6 -  6
Amortization  3 -  3
Interest expense, net  2 -  2
Other  2 -  2
Non-GAAP Operating income $15 - $25

Note: Amounts may not calculate precisely due to rounding.

 


Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2022 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.